GE Healthcare ($GE) is continuing its quest to grab more genomic sequencing business, this time by snatching up contract genomic researcher SeqWright for an undisclosed price.
Founded in 1994, Houston-based SeqWright offers contract DNA sequencing and a number of other related molecular biotechnology products and services, according to its website. GE Healthcare says it will partner its latest acquisition with its Clarient unit, which focuses more on protein and gene expression profiling to support pharmaceutical and in vitro diagnostics studies.
The deal will help boost GE Healthcare's contract and other services for biopharmaceutical, diagnostic and research industry clients, "and eventually to patients and health care providers," according to Pascale Witz, president and CEO of the company's medical diagnostics division.
Earlier this week, GE Healthcare announced it had inked a licensing deal with Dyax ($DYAX) to develop and commercialize new molecular diagnostic and cancer biomarker technology. The company has pursued acquisitions to boost its efforts in molecular diagnostics, companion diagnostics and personalized medicine.
- here's the release
- and the Genome Web story (reg. req.)